Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease

키워드

참고문헌 (63)

1. Yun Kyu Oh, "Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients", The Korean Journal of Internal Medicine, 36(4), pp.767~779 (2021), 대한내과학회[DOI]
2. Chebib FT, "Autosomal dominant polycystic kidney disease : core curriculum 2016", Am J Kidney Dis, 67, pp.792~810 (2016)
3. Jones TJ, "Mechanosensory calcium signaling", Adv Exp Med Biol, 740, pp.1001~1015 (2012)
4. Torres VE, "Mechanisms of disease : autosomal dominant and recessive polycystic kidney diseases", Nat Clin Pract Nephrol, 2, pp.40~55 (2006)
5. Chebib FT, "Vasopressin and disruption of calcium signalling in polycystic kidney disease", Nat Rev Nephrol, 11, pp.451~464 (2015)
6. Bichet DG, "Central vasopressin : dendritic and axonal secretion and renal actions", Clin Kidney J, 7, pp.242~247 (2014)
7. Yeonhee Lee, "Korean Society of Nephrology 2022 recommendations on controversial issues in diagnosis and management of hyponatremia", The Korean Journal of Internal Medicine, 37(6), pp.1120~1137 (2022), 대한내과학회[DOI]
8. Meijer E, "Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease", Clin J Am Soc Nephrol, 6, pp.361~368 (2011)
9. Baur BP, "Review of tolvaptan for autosomal dominant polycystic kidney disease", Pharmacotherapy, 34, pp.605~616 (2014)
10. Reif GA, "Tolvaptan inhibits ERK-dependent cell proliferation, Cl– secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin", Am J Physiol Renal Physiol, 301, pp.F1005~F1013 (2011)
11. Torres VE, "Tolvaptan in later-stage autosomal dominant polycystic kidney disease", N Engl J Med, 377, pp.1930~1942 (2017)
12. Torres VE, "Tolvaptan in patients with autosomal dominant polycystic kidney disease", N Engl J Med, 367, pp.2407~2418 (2012)
13. Yeshwanter Radhakrishnan, "Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options", Kidney Research and Clinical Practice, 41(4), pp.422~431 (2022), 대한신장학회[DOI]
14. Harris PC, "Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease", J Am Soc Nephrol, 17, pp.3013~3019 (2006)
15. Bae KT, "Imaging for the prognosis of autosomal dominant polycystic kidney disease", Nat Rev Nephrol, 6, pp.96~106 (2010)
16. 박혜인, "Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study", Kidney Research and Clinical Practice, 41(4), pp.432~441 (2022), 대한신장학회[DOI]
17. Jung Y, "Using the Mayo imaging classification to predict renal outcomes in Korean autosomal dominant polycystic kidney disease patients", Kidney Res Clin Pract, 41, pp.389~392 (2022)
18. Reddy B, "Acute response to tolvaptan in ADPKD : a window to predict long-term efficacy?", Am J Kidney Dis, 65, pp.811~813 (2015)
19. Torres VE, "Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease : the TEMPO 4 : 4trial", Nephrol Dial Transplant, 33, pp.477~489 (2018)
20. Muto S, "The effect of tolvaptan on autosomal dominant polycystic kidney disease patients : a subgroup analysis of the Japanese patient subset from TEMPO 3 : 4 trial", Clin Exp Nephrol, 19, pp.867~877 (2015)
21. Torres VE, "Tolvaptan in ADPKD patients with very low kidney function", Kidney Int Rep, 6, pp.2171~2178 (2021)
22. Xie X, "Effectiveness of tolvaptan in the treatment for patients with autosomal dominant polycystic kidney disease : a meta-analysis", Comb Chem High Throughput Screen, 23, pp.6~16 (2020)
23. Naranjo J, "Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease", Front Med(Lausanne), 9, pp.987092~ (2022)
24. Chebib FT, "A practical guide for treatment of rapidly progressive ADPKD with tolvaptan", J Am Soc Nephrol, 29, pp.2458~2470 (2018)
25. Bennett H, "Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease : an exploratory analysis using the ADPKD outcomes model", BMC Nephrol, 20, pp.136~ (2019)
26. Bajwa ZH, "Pain management in polycystic kidney disease", Kidney Int, 60, pp.1631~1644 (2001)
27. Casteleijn NF, "Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease : secondary analysis from a randomized controlled trial", Am J Kidney Dis, 69, pp.210~219 (2017)
28. Torres VE, "Renal stone disease in autosomal dominant polycystic kidney disease", Am J Kidney Dis, 22, pp.513~519 (1993)
29. Nishiura JL, "Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients", Clin J Am Soc Nephrol, 4, pp.838~844 (2009)
30. Cheungpasitporn W, "Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations", J Urol, 195, pp.1476~1481 (2016)
31. Raina R, "Clinical utility and tolerability of tolvaptan in the treatment of autosomal dominant polycystic kidney disease(ADPKD)", Drug Healthc Patient Saf, 14, pp.147~159 (2022)
32. Devuyst O, "Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease : results from TEMPO 3 : 4", Kidney Int Rep, 2, pp.1132~1140 (2017)
33. Anderegg MA, "Quality of life in autosomal dominant polycystic kidney disease patients treated with tolvaptan", Kidney Med, 2, pp.162~171 (2020)
34. Torres VE, "Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease", Clin J Am Soc Nephrol, 16, pp.48~58 (2020)
35. Kramers BJ, "Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease", Kidney Int, 98, pp.989~998 (2020)
36. Kramers BJ, "Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan", Am J Kidney Dis, 73, pp.354~362 (2019)
37. 신진호, "The roles of sodium and volume overload on hypertension in chronic kidney disease", Kidney Research and Clinical Practice, 40(4), pp.542~554 (2021), 대한신장학회[DOI]
38. Gang-Jee Ko, "How important is dietary management in chronic kidney disease progression? A role for low protein diets", The Korean Journal of Internal Medicine, 36(4), pp.795~806 (2021), 대한내과학회[DOI]
39. Kramers BJ, "Case report : a thiazide diuretic to treat polyuria induced by tolvaptan", BMC Nephrol, 19, pp.157~ (2018)
40. Shoaf SE, "Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide", J Cardiovasc Pharmacol, 50, pp.213~222 (2007)
41. Watkins PB, "Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease : analysis of clinical trials database", Drug Saf, 38, pp.1103~1113 (2015)
42. Endo M, "Role of liver transplantation in tolvaptan-associated acute liver failure", Kidney Int Rep, 4, pp.1653~1657 (2019)
43. Gansevoort RT, "Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease : a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice", Nephrol Dial Transplant, 31, pp.337~348 (2016)
44. Müller RU, "An update on the use of tolvaptan for autosomal dominant polycystic kidney disease : consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International", Nephrol Dial Transplant, 37, pp.825~839 (2022)
45. Bhatt PR, "Review of tolvaptan’s pharmacokinetic and pharmacodynamic properties and drug interactions", J Clin Med, 3, pp.1276~1290 (2014)
46. Torres VE, "Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage : results from the TEMPO 3 : 4 trial", Clin J Am Soc Nephrol, 11, pp.803~811 (2016)
47. 송수현, "Hyperuricemia is a risk factor for the progression to end-stage renal disease in minimal change disease", Kidney Research and Clinical Practice, 40(3), pp.411~418 (2021), 대한신장학회[DOI]
48. Yousuf Waheed, "Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease", The Korean Journal of Internal Medicine, 36(6), pp.1281~1293 (2021), 대한내과학회[DOI]
49. Oguro M, "Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease", J Nephrol, 31, pp.961~966 (2018)
50. Higashihara E, "Long-term outcomes of longitudinal efficacy study with tolvaptan in ADPKD", Kidney Int Rep, 7, pp.270~281 (2022)
51. "Commentary on the NICE Guideline on Tolvaptan for treating autosomal dominant polycystic kidney disease" (2016)[URL]
52. Horie S, "Evidence-based clinical practice guidelines for polycystic kidney disease 2014", Clin Exp Nephrol, 20, pp.493~509 (2016)
53. Nishio S, "A digest from evidence-based clinical practice guideline for polycystic kidney disease 2020", Clin Exp Nephrol, 25, pp.1292~1302 (2021)
54. Alpers DH, "Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease(ADPKD) : an analysis of pivotal clinical trials", Am J Kidney Dis, 81, pp.281~293 (2023)
55. Casteleijn NF, "Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease : reliable indicators of vasopressin activity and disease prognosis?", Am J Nephrol, 41, pp.248~256 (2015)
56. Grantham JJ, "The importance of total kidney volume in evaluating progression of polycystic kidney disease", Nat Rev Nephrol, 12, pp.667~677 (2016)
57. Michell RH, "Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin", Biochem Soc Trans, 7, pp.861~865 (1979)
58. Mangoo-Karim R, "Renal epithelial fluid secretion and cyst growth : the role of cyclic AMP", FASEB J, 3, pp.2629~2632 (1989)
59. Yamaguchi T, "Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease", Am J Kidney Dis, 30, pp.703~709 (1997)
60. Yamamura Y, "OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist", Science, 252, pp.572~574 (1991)
61. Gattone VH 2nd, "Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease", Dev Genet, 24, pp.309~318 (1999)
62. Gattone VH 2nd, "Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist", Nat Med, 9, pp.1323~1326 (2003)
63. Higashihara E, "Tolvaptan in autosomal dominant polycystic kidney disease : three years’experience", Clin J Am Soc Nephrol, 6, pp.2499~2507 (2011)

관련 논문AI추천